Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: SBS, FVT

TriNet Webinar: Weathering the Storm--Critical Considerations for SMBs to Navigate the Current Banking Crisis


DUBLIN, Calif., March 24, 2023 /PRNewswire/ --

WHAT:

TriNet Webinar: Weathering the Storm ? Critical Considerations for SMBs to Navigate the Current Banking Crisis




As businesses work to stay afloat through the uncharted waters of the recent banking crisis, TriNet experts are here to help small and medium-sized businesses through these stormy and uncertain times. Buoyed by 30+ years of experience helping SMBs steer through the challenges brought on by COVID-19, recessions, numerous laws and policy changes affecting SMBs, TriNet has been there to help SMBs not just survive but thrive. There is no substitute for experience when it comes to helping SMBs stay on course during a crisis.  



WHO:

Samantha Wellington - Executive Vice President, Business Affairs, and Chief Legal Officer, TriNet




Alex Warren - Chief Revenue Officer, TriNet



WHEN:

Thursday, March 30, 2023, at 10 a.m. PT / 1 p.m. ET



WHERE:

Register here to join the webinar.

About TriNet
TriNet (NYSE: TNET) provides small and medium-size businesses (SMBs) with full-service HR solutions tailored by industry. To free SMBs from HR complexities, TriNet offers access to human capital expertise, benefits, risk mitigation and compliance, payroll, all enabled by industry leading technology capabilities. TriNet's suite of products also includes?services and software-based solutions to help streamline workflows by connecting HR, Benefits, Employee Engagement, Payroll and Time & Attendance. From Main Street to Wall Street, TriNet empowers SMBs to focus on what matters?most?growing their business and enabling their people. TriNet, incredible starts here. For more information, visit TriNet.com or follow us on Twitter.

Investors:

Media:


Alex Bauer

Renee Brotherton/Josh Gross


TriNet

TriNet


[email protected]

[email protected]



[email protected]  


TriNet and the TriNet logo are registered trademarks of TriNet. All other trademarks, service marks, registered trademarks, or registered service marks are the property of their respective owners.

SOURCE TriNet Group, Inc.


These press releases may also interest you

at 12:30
The Integritus Group Inc. Expands Its Portfolio with the Acquisition of LPM Media Group
The Integritus Group., a prominent loss prevention and regulatory compliance firm, announced today the acquisition of LPM Media Group, the industry leading communications company specializing in digital, mobile, and print awareness and e-learning...

at 12:00
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVersetm Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
?  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses?? ? ...

at 11:11
Menswear Brand Highland Duds Introduces The Stack
Direct-to-consumer menswear label, Highland Duds, announces the launch of The Stack: an innovative shopping solution designed to make styling smarter, not harder....

at 09:10
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Notably, Exai's platform maintained...

at 09:05
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
Cyteir Therapeutics, Inc. ("Cyteir") , a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate...

at 09:05
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
Merck , known as MSD outside of the United States and Canada, today announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment...

More news about Science and technology...


News published on and distributed by: